pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·Sep 25·1 min read
save

NIH deputy director Nicole Kleinstreuer leads push to cut animal testing with new policies

Sep 25, 2026·read at Fierce Biotech ↗RegulatoryPositive

NIH has spent the past 18 months accelerating policies aimed at reducing the use of animals in research.

The effort is being directed by Dr. Nicole Kleinstreuer, the agency’s deputy director for program coordination, planning and strategic initiatives, who reports to Director Jay Bhattacharya.

Kleinstreuer’s portfolio includes programs in women’s health, disease prevention, data science and dietary supplements, and she emphasizes moving toward human-based scientific approaches.

Her career includes a bioengineering and mathematics degree, a PhD in biomedical engineering, more than a decade at NIH and nearly two decades working with human-based models before joining the agency.

The new policies aim to replace animal experiments with modern alternatives while managing potential backlash from stakeholders.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “How NIH’s Nicole Kleinstreuer is working to reduce animal testing while avoiding a ‘backlash’”

read at Fierce Biotech ↗
1,634 words · retrieved 2d ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
National Institutes of Health4AMGENBOEHRINGER INGELHEIMBoehringer Ingelheim CorpMerck KGaAPFIZER
drugs
Small Molecules
topics
Hepatology4Oncology2ApprovalCardiologyNephrologyPulmonologyWomen's Health

related stories

  • 10h agoCaribou to stop R&D work, start ‘substantial’ job cutsBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Matchpoint makes $150M; KymaThera corrals $80MFierce Biotech
  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Sep 24Chutes & Ladders—Travere chief makes way for former Amicus CEOFierce Biotech